IL10 and metabolic syndrome: These results are consistent with the report by Satoh-Asahara et al. that demonstrate that IL-10 expression in circulating monocytes increases in obese patients with dyslipidemia after 3 months of treatment with EPA (1.8 g daily); interestingly, these patients exhibited a decrease in arterial stiffness (38).